Patricia Maria Bergamo Favaro

• Abstract

  FMNL1 is predominantly expressed in peripheral blood leukocytes, spleen and thymus. However, this protein is highly expressed in several hematologic malignancies. We have recently demonstrated the role of FMNL1 in proliferation, and migration cells in Namalwa cell line (Burkitt's lymphoma), which suggests its contribution to the leukemogenesis. Next, our group conducted a microarray assay…

  Characterization of FMNL1 in the leukemic process and normal hematopoiesis, AP.R

• Abstract

  Currently it is clear the participation of different signaling pathways involved in both the development and the maintenance of hematologic malignancies. The constitutive activation of PI3K/Akt/mTOR signaling pathway is well described in acute lymphoblastic leukemia T cells (T-ALL), and recently it was found that the activity of PI3K cooperates with the development of Burkitt's lymphoma. …

  Study of therapeutic targets in hematologic malignancies, AP.R

• Abstract

  The present project aims at investigating the factors involved in the self-renewal and maintenance of bone marrow neoplastic cells, as occurs in myelodysplasia, acute leukemias, and multiple myeloma. The common aspect between them all is that they all occur in high frequency in the population, and despite the considerable therapeutic advances achieved during the last decade, still have a …

  Biology of neoplastic diseases of bone marrow, AP.TEM

(Only some records are available in English at this moment)

• Abstract

  Nowadays, allogeneic hematopoietic cell transplantation is the cure for several patients with benign and malignant hematologic diseases. Many complications can occur after bone marrow transplant and the Graft-versus-host disease (GVHD) is one of the most important due to mortality and impact on quality of life. Approximately 50% of patients have some manifestation of chronic GVHD, althoug…

  Characterization of TGF-b signaling in the chronic graft-versus-host disease after allogeneic bone marrow transplant, BP.IC

• Abstract

  In addition to its support role during hematopoiesis, either by secretion of soluble factors or cell-cell interactions, recently, mesenchymal stem cells (MSCs) have become candidates for cell therapy, mainly because of its immunomodulatory capacity. Myelodysplastic syndromes (MDS) are hematologic malignancies that result from changes in hematopoietic stem cell characterized by ineffective…

  The role of IL32 in the immunemodulation of mesenchymal stem cell and the stromal-hematopoietic interection in myelodysplastic syndrome, BP.DR
• Inhibition of the expression of FMNL1 protein in lymphoid neoplasia: a new strategy for targeted therapy?, BP.PD